WuHui

Huahui Health is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of innovative therapies for viral hepatitis, liver diseases, and oncology. Founded by Dr. Wenhui Li, the scientist who discovered the NTCP receptor for HBV and HDV, the company leverages deep expertise in viral entry mechanisms to create first-in-class treatments. Its lead candidate, Libevitug (HH-003), is a neutralizing monoclonal antibody targeting the NTCP receptor, currently in pivotal Phase II trials for chronic hepatitis D. Huahui Health's pipeline also includes HH-006, an entry inhibitor for HBV/HDV, and several programs in oncology and other liver-related conditions. The company is backed by prominent investors and aims to provide functional cures for patients suffering from chronic viral infections.